Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Vaccines|July 27, 2026
Leveraging Large Language Models to Address Common Vaccination Myths and MisconceptionsFlorian Reis, Lea J Bayer, Claudius Malerczyk, et al.Expert Review of Vaccines|December 18, 2024
Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in GermanyAhuva Averin, Bennet Huebbe, Mark Atwood, et al.Journal of Medical Economics|August 6, 2024
Economic burden of respiratory syncytial virus in adults in Germany - a health claims analysis between 2015 and 2018Bennet Huebbe, Anja Mocek, Karina C Manz, et al.Infectious Diseases and Therapy|April 15, 2026
Cost-Effectiveness of Alternative Immunization Strategies to Protect Infants Against Respiratory Syncytial Virus in Germany: A Decision Modeling StudyCaroline Lade, Erin Quinn, Lea J Bayer, et al.Expert Review of Vaccines|July 31, 2026
Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in GermanyErin Quinn, Mary MacKinnon, Severin Freisberg, et al.Journal of Clinical Medicine|November 13, 2025
RSV Monitoring in Germany: A Critical Overview of Available Surveillance SystemsLea J Bayer, Christian Brösamle, Gordon Brestrich, et al.The Journal of Infection|February 14, 2025
Incidence of RSV-related hospitalizations for ARIs, including CAP: Data from the German prospective ThEpiCAP studyCaihua Liang, Elizabeth Begier, Stefan Hagel, et al.Influenza and Other Respiratory Viruses|April 28, 2025
Estimated Incidence Rate of Specific Types of Cardiovascular and Respiratory Hospitalizations Attributable to Respiratory Syncytial Virus Among Adults in Germany Between 2015 and 2019Caihua Liang, Aleksandra Polkowska-Kramek, Caroline Lade, et al.Pageof 1